secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001299130-26-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q4 revenue $44.6M, consumable record; GAAP net loss $40.4M, non-GAAP loss narrows
--------------------------------------------------------------------------------

- Q4 revenue $44.6M (+14% YoY); consumable revenue record $21.6M (+15% YoY).
- GAAP net loss $40.4M ($0.13/share) vs GAAP net income $2.4M in Q4 2024 (incl $154.4M debt restructuring gain).
- Non-GAAP net loss $37.6M ($0.12/share) vs $55.3M ($0.20) in Q4 2024; non-GAAP gross margin 40% vs 31%.
- Vega placements 42 in Q4 (140 FY); Revio placements 21 Q4 (61 FY). Annualized Revio pull-through ~$242,000.
- Completed sale of short-read assets for ~$48.1M net cash; cash & investments $279.5M at year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913026000017/0001299130-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913026000017/pacb-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001299130-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer